|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6291159B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
|
US6641809B1
(en)
|
1990-03-26 |
2003-11-04 |
Bristol-Myers Squibb Company |
Method of regulating cellular processes mediated by B7 and CD28
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
|
US5871907A
(en)
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
EP0606217B2
(en)
|
1991-06-27 |
2008-12-03 |
Bristol-Myers Squibb Company |
Ctl4a receptor, fusion proteins containing it and uses thereof
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
US6482919B2
(en)
|
1993-02-01 |
2002-11-19 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
|
US5942607A
(en)
|
1993-07-26 |
1999-08-24 |
Dana-Farber Cancer Institute |
B7-2: a CTLA4/CD28 ligand
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
AU737910B2
(en)
|
1997-01-31 |
2001-09-06 |
Regents Of The University Of California, The |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6730512B2
(en)
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
EP1012280B1
(en)
|
1997-06-11 |
2004-11-10 |
Borean Pharma A/S |
Trimerising module
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
GB9823071D0
(en)
|
1998-10-21 |
1998-12-16 |
Affibody Technology Ab |
A method
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
DE60044247D1
(de)
|
1999-04-30 |
2010-06-02 |
Inst Rech S Cliniques De Montr |
Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
|
|
GB9917027D0
(en)
|
1999-07-20 |
1999-09-22 |
Affibody Technology Sweeden Ab |
In vitro selection and optional identification of polypeptides using solid support carriers
|
|
PT1218504E
(pt)
|
1999-09-21 |
2007-10-22 |
Genetics Inst Llc |
Novas moléculas gl50 e suas utilizações
|
|
ATE360031T1
(de)
|
2000-01-03 |
2007-05-15 |
Tr Associates L L C |
Chimäre proteine und anwendungen
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
PE20011338A1
(es)
|
2000-05-26 |
2002-01-13 |
Bristol Myers Squibb Co |
Moleculas mutantes de ctla4 solubles
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
AU2001272978A1
(en)
|
2000-06-23 |
2002-01-08 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
|
EP1320599A2
(en)
|
2000-06-28 |
2003-06-25 |
Genetics Institute, LLC |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
|
SI1935427T1
(en)
|
2000-07-03 |
2018-05-31 |
Bristol-Myers Squibb Company |
USE OF HEATED CTLA4 MUTANT MOLECULES
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
PL204899B1
(pl)
|
2001-05-23 |
2010-02-26 |
Bristol Myers Squibb Co |
Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
|
|
EP1497426A2
(en)
|
2001-06-22 |
2005-01-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
JP4572276B2
(ja)
|
2001-06-29 |
2010-11-04 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ |
Ｔ細胞調節遺伝子およびその使用方法
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US7235631B2
(en)
|
2002-02-07 |
2007-06-26 |
Mayo Foundation For Medical Education And Research |
ICOS mutants
|
|
US7223408B2
(en)
*
|
2002-10-03 |
2007-05-29 |
Wyeth Holdings Corporation |
Human papillomavirus polypeptides and immunogenic compositions
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
EP1944320A1
(en)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
US7332303B2
(en)
|
2002-12-23 |
2008-02-19 |
Bristol-Myers Squibb Company |
Product quality enhancement in mammalian cell culture processes for protein production
|
|
WO2004072286A1
(ja)
|
2003-01-23 |
2004-08-26 |
Ono Pharmaceutical Co., Ltd. |
ヒトｐｄ−１に対し特異性を有する物質
|
|
NZ545314A
(en)
|
2003-08-04 |
2009-03-31 |
Bristol Myers Squibb Co |
Methods for treating cardiovascular disease using a soluble CTLA4 molecule
|
|
CN103755800B
(zh)
|
2004-02-02 |
2016-02-24 |
Ambrx公司 |
经修饰的人类生长激素多肽与其用途
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
US7638299B2
(en)
|
2004-07-21 |
2009-12-29 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
NZ555353A
(en)
|
2004-11-22 |
2009-12-24 |
Anaphore Inc |
TNF antagonists
|
|
US7385028B2
(en)
|
2004-12-22 |
2008-06-10 |
Ambrx, Inc |
Derivatization of non-natural amino acids and polypeptides
|
|
SI1868635T1
(sl)
|
2005-04-06 |
2017-07-31 |
Bristol-Myers Squibb Company |
Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami
|
|
SI1954710T1
(sl)
|
2005-11-08 |
2011-08-31 |
Ambrx Inc |
Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
|
|
PL2253644T3
(pl)
|
2005-12-20 |
2014-04-30 |
Bristol Myers Squibb Co |
Kompozycje i sposoby wytwarzania kompozycji
|
|
WO2008030558A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
AU2007331672A1
(en)
|
2006-12-15 |
2008-06-19 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
|
PL2856876T3
(pl)
|
2007-03-30 |
2018-06-29 |
Memorial Sloan-Kettering Cancer Center |
Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
|
|
KR20100019467A
(ko)
|
2007-05-02 |
2010-02-18 |
암브룩스, 인코포레이티드 |
변형된 인터페론 베타 폴리펩티드 및 그의 용도
|
|
AU2008293885A1
(en)
|
2007-07-13 |
2009-03-05 |
The John Hopkins University |
B7-DC variants
|
|
PT2222697E
(pt)
|
2007-11-01 |
2013-02-15 |
Perseid Therapeutics Llc |
Polipeptídeos imunossupressores e ácidos nucleicos
|
|
US11260133B2
(en)
|
2008-02-21 |
2022-03-01 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to peptides and proteins with C-terminal elements
|
|
US20110015345A1
(en)
|
2008-03-19 |
2011-01-20 |
Ambrx, Inc. |
Modified FGF-23 Polypeptides and Their Uses
|
|
EP3208612B1
(en)
|
2008-04-09 |
2019-09-18 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US7915222B2
(en)
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
|
WO2009147137A1
(en)
|
2008-06-02 |
2009-12-10 |
Institut Gustave Roussy |
NATURAL KILLER p30 (NKp30) DYSFUNCTION AND THE BIOLOGICAL APPLICATIONS THEREOF
|
|
US9931386B2
(en)
|
2008-06-16 |
2018-04-03 |
Atsuo Ochi |
Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
|
|
MX2011000859A
(es)
|
2008-07-23 |
2011-02-24 |
Ambrx Inc |
Polipeptidos g-csf bovinos modificados y sus usos.
|
|
JP2012500652A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
標的化共刺激ポリペプチドおよび癌を処置するための使用方法
|
|
ES2545609T3
(es)
|
2008-08-25 |
2015-09-14 |
Amplimmune, Inc. |
Composiciones de antagonistas de PD-1 y métodos de uso
|
|
PL2342223T3
(pl)
|
2008-09-26 |
2017-09-29 |
Ambrx, Inc. |
Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
|
|
AU2010210605B2
(en)
|
2009-02-04 |
2015-08-13 |
Board Of Regents, The University Of Texas System |
Dual targeting of miR-208 and miR-499 in the treatment of cardiac disorders
|
|
AU2010282340B2
(en)
*
|
2009-08-13 |
2016-12-22 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
CN104826106B
(zh)
|
2009-09-30 |
2019-01-11 |
斯隆凯特林防癌纪念中心 |
用于治疗癌症的组合免疫疗法
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
EP2531216B1
(en)
|
2010-02-04 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
PL3053932T3
(pl)
|
2010-02-19 |
2021-03-08 |
Xencor, Inc. |
Nowe immunoadhezyny CTLA4-IG
|
|
PT2542590T
(pt)
|
2010-03-05 |
2017-08-31 |
Univ Johns Hopkins |
Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
|
|
EP2545073B1
(en)
|
2010-03-12 |
2015-09-30 |
AbbVie Biotherapeutics Inc. |
Ctla4 proteins and their uses
|
|
CN103261217B
(zh)
*
|
2010-11-11 |
2017-04-26 |
港大科桥有限公司 |
可溶性 pd‑1变体、融合构建体及其用途
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
ES2608835T3
(es)
|
2011-04-13 |
2017-04-17 |
Bristol-Myers Squibb Company |
Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
|
|
US9409987B2
(en)
|
2011-04-15 |
2016-08-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
TWI496886B
(zh)
|
2011-06-24 |
2015-08-21 |
Taipei Veteran General Hospital |
提升感染性與惡性疾病之治療之免疫反應
|
|
PT2726101T
(pt)
*
|
2011-06-30 |
2018-11-21 |
Genzyme Corp |
Inibidores da ativação de células t
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
CA2865578C
(en)
|
2012-02-27 |
2023-01-17 |
Amunix Operating Inc. |
Xten conjugate compositions and methods of making same
|
|
WO2013148049A1
(en)
|
2012-03-29 |
2013-10-03 |
The General Hospital Corporation |
Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
|
|
ES2777778T3
(es)
|
2012-05-11 |
2020-08-06 |
Medimmune Ltd |
Variantes de CTLA-4
|
|
CA2875980A1
(en)
|
2012-06-06 |
2013-12-12 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the hippo pathway and uses thereof
|
|
EP2866823A4
(en)
|
2012-06-27 |
2016-03-02 |
Orban Biotech Llc |
CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
AU2013355379B2
(en)
|
2012-12-04 |
2018-08-09 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9944689B2
(en)
|
2013-03-07 |
2018-04-17 |
The General Hospital Corporation |
Human CTLA4 mutants and use thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
US20160271218A1
(en)
|
2013-06-27 |
2016-09-22 |
Mor Research Applications Ltd. |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
|
TWI888366B
(zh)
|
2013-07-16 |
2025-07-01 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
|
|
JP2017508446A
(ja)
|
2014-01-28 |
2017-03-30 |
北京韓美薬品有限公司 |
二機能性融合タンパク質及びその製造方法並びに使用
|
|
ES2792849T3
(es)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
|
|
SG11201608848XA
(en)
|
2014-04-25 |
2016-11-29 |
Bristol Myers Squibb Co |
Use of ctla4 compound for achieving drug-free remission in subjects with early ra
|
|
PE20170140A1
(es)
|
2014-07-16 |
2017-03-30 |
Genentech Inc |
Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
|
|
EP3552615B8
(en)
|
2014-07-16 |
2022-03-02 |
Transgene |
Oncolytic virus for expression of immune checkpoint modulators
|
|
PL3177640T3
(pl)
|
2014-08-08 |
2020-11-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
|
|
CA2959105C
(en)
|
2014-09-03 |
2023-10-17 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
CN107207597A
(zh)
|
2014-11-06 |
2017-09-26 |
儿研所儿童医学中心 |
用于癌症和自身免疫疾病的免疫疗法
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
US10953045B2
(en)
|
2015-04-02 |
2021-03-23 |
Cancure Limited |
Agents and compositions for eliciting an immune response
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
RS61943B1
(sr)
|
2015-04-17 |
2021-07-30 |
Alpine Immune Sciences Inc |
Imunomodulatorni proteini sa prilagodljivim afinitetima
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
EA035412B1
(ru)
|
2015-05-29 |
2020-06-10 |
Бристол-Майерс Сквибб Компани |
Антитела к ox40 и их применение
|
|
AU2016298227B9
(en)
|
2015-07-30 |
2019-10-31 |
Macrogenics, Inc. |
PD-1-binding molecules and methods of use thereof
|
|
WO2017023779A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
AU2016303485A1
(en)
|
2015-07-31 |
2018-03-01 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
CN107921093B
(zh)
|
2015-08-20 |
2022-04-01 |
弗劳恩霍夫应用研究促进协会 |
用于治疗和预防器官衰竭的b7-h1融合多肽
|
|
EA201890729A1
(ru)
|
2015-09-14 |
2018-09-28 |
Элпайн Имьюн Сайнс, Инк. |
Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
|
|
AU2016333517B2
(en)
|
2015-10-02 |
2023-09-07 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
|
JP6936221B2
(ja)
|
2015-11-02 |
2021-09-15 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
|
|
JP7148399B2
(ja)
|
2015-11-04 |
2022-10-05 |
タイペイ・ベテランズ・ジェネラル・ホスピタル |
悪性疾患に対する併用療法
|
|
JP6955507B2
(ja)
|
2015-12-14 |
2021-10-27 |
マクロジェニクス，インコーポレーテッド |
Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
|
|
CA3014458A1
(en)
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
MX2018012472A
(es)
|
2016-04-15 |
2019-08-12 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
|
|
IL310729A
(en)
|
2016-04-15 |
2024-04-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins that are variants of CD80 and their uses
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
BR112019007281A2
(pt)
|
2016-10-14 |
2019-07-09 |
Xencor Inc |
proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
EP3596114A2
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
JP2020511144A
(ja)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
|
|
IL320149A
(en)
|
2017-03-16 |
2025-06-01 |
Alpine Immune Sciences Inc |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
WO2019074983A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
|
|
JP7282760B2
(ja)
|
2017-10-18 |
2023-05-29 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
|
|
WO2019136179A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
KR20210089146A
(ko)
|
2018-09-19 |
2021-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
|
|
JP2023517044A
(ja)
|
2020-03-09 |
2023-04-21 |
ファイザー・インク |
融合タンパク質およびその使用
|
|
US20250243260A1
(en)
|
2022-03-07 |
2025-07-31 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
|